May 2017

Updates to the NCCN guidelines for the management of advanced NSCLC stress the importance of multiplexed biomarker testing at diagnosis to aid in the selection of appropriate first-line and subsequent lines of therapy.

Much research has been done to define the role of neoadjuvant and adjuvant therapies in metastatic renal cell carcinoma patients who have diseease recurrence after surgical resection, but the standard of care has not significantly changed.

Our understanding of the genomic landscape of metastatic castration-resistant prostate cancer has been rapidly progressing, with new clinical data emerging to clarify and, in many cases, support the use of PARP inhibitors in the treatment of these patients.

The genetic profile of treatment-resistant non-small cell lung cancer may be more complex than initially thought, according to a presentation by Zofia Piotrowska, MD.

The NCCN published its first set of guidelines for myeloproliferative neoplasms in October 2016 and is already looking to update and expand these guidelines to match the need for direction in diagnosing and treating patients with MPNs.

An overview of updated guidelines for the management of invasive breast cancer, issued by the National Comprehensive Cancer Network.

Outcomes have significantly improved for patients with melanoma in the wake of newer targeted treatments. Yet, brain metastases from melanoma remain a significant unmet need, with up to 60% of patients with advanced melanoma developing brain metastases.